NASDAQ:EXOZ eXoZymes (EXOZ) Stock Price, News & Analysis $9.84 -0.24 (-2.38%) As of 12:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About eXoZymes Stock (NASDAQ:EXOZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get eXoZymes alerts:Sign Up Key Stats Today's Range$9.84▼$9.8450-Day Range$9.15▼$14.9052-Week Range$8.50▼$23.99Volume410 shsAverage Volume15,377 shsMarket Capitalization$82.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV. Read More Receive EXOZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for eXoZymes and its competitors with MarketBeat's FREE daily newsletter. Email Address EXOZ Stock News HeadlineseXoZymes Increases CEO Compensation PackageJune 20, 2025 | tipranks.comBringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025 | globenewswire.comTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.August 4 at 2:00 AM | Porter & Company (Ad)BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025 | globenewswire.comeXoZymes Inc. Reports 2024 Progress and IPO SuccessApril 2, 2025 | tipranks.comeXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025 | globenewswire.comeXoZymes Provides Fourth Quarter and Full Year 2024 UpdateApril 2, 2025 | globenewswire.comeXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025March 26, 2025 | globenewswire.comSee More Headlines EXOZ Stock Analysis - Frequently Asked Questions How have EXOZ shares performed this year? eXoZymes' stock was trading at $17.39 at the beginning of the year. Since then, EXOZ shares have decreased by 42.1% and is now trading at $10.07. How were eXoZymes' earnings last quarter? eXoZymes Inc. (NASDAQ:EXOZ) issued its quarterly earnings results on Monday, May, 12th. The company reported ($0.22) earnings per share (EPS) for the quarter. Read the conference call transcript. How do I buy shares of eXoZymes? Shares of EXOZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2025Today8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EXOZ CIK2010788 WebN/A Phone(626) 415-1488FaxN/AEmployees29Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.52 Quick Ratio6.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / Book7.87Miscellaneous Outstanding Shares8,368,000Free Float2,309,000Market Cap$82.34 million OptionableN/A BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:EXOZ) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.